Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: A propensity analysis of the AURA-LV and AURORA 1 studies and ALMS
Lupus Science & Medicine 2024;11:e001319 DOI: 10.1136/lupus-2024-001319
Dall’Era et al. conducted a propensity analysis to compare voclosporin-based triple immunosuppressive therapy with high-dose GC-based regimens for active LN. Voclosporin showed fewer AEs, improved safety, and significantly reduced proteinuria over six months, suggesting a superior risk-benefit profile for patients with lupus nephritis.
The study utilised data from Phase 2 and 3 clinical trials and the Aspreva Lupus Management Study to compare safety and efficacy outcomes of voclosporin with high-dose GCs and mycophenolate mofetil or intravenous cyclophosphamide. The aim was to assess proteinuria reduction and safety within six months
Keywords:
